PROCEPT BIOROB. DL-,00001 Aktie

PROCEPT BioRobotics reported a 19% revenue increase to $94.5 million in Q2 2026, beating analyst expectations. Adjusted earnings per share were -$0.47, slightly missing estimates. Management lowered its forecast for the number of US procedures to 54,000–56,000 but kept the annual revenue guidance unchanged at $390–410 million. After-hours trading saw the stock fall about 4.5% on the reduced procedure outlook. » Altro su de.investing.com

Shares of Procept Biorobotics fell to a 52-week low of $17.95, about 70% below the year high of $60.57. InvestingPro sees a fair value of $26.23 at this price and notes the company has more cash than debt despite not being profitable over the past twelve months. Clinically, Procept completed enrollment for the randomized WATER IV study and received an Investigational Device Exemption from the FDA for a second randomized protocol; primary endpoint results are expected for the AUA annual meeting in 2027. Analyst reactions are mixed: Truist and Leerink downgraded the stock (to Hold/Market Perform) with reduced price targets, while Evercore ISI issued an Outperform rating with a $30 target. » Altro su de.investing.com

PROCEPT BioRobotics has completed recruitment for the first randomized WATER‑IV study with 280 patients, which compares Aquablation with radical prostatectomy, and expects to present primary endpoints at the AUA annual meeting in 2027. The FDA approved a second randomized protocol of up to 333 patients that will compare Aquablation with active surveillance in grade 1 and 2 prostate cancer and includes a ten‑year follow‑up. Both studies assess disease control and quality of life, including urinary and sexual function. PROCEPT most recently reported revenue growth of 29% to $322 million, a gross margin of 64% and EPS of -$1.83, with a market capitalization of $1.51 billion. » Altro su de.investing.com